NewAmsterdam Pharma (NASDAQ:NAMS) CAO Louise Frederika Kooij Sells 105,000 Shares

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) CAO Louise Frederika Kooij sold 105,000 shares of the business’s stock in a transaction on Monday, July 20th. The shares were sold at an average price of $30.34, for a total transaction of $3,185,700.00. Following the sale, the chief accounting officer directly owned 24,353 shares of the company’s stock, valued at approximately $738,870.02. The trade was a 81.17% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Louise Frederika Kooij also recently made the following trade(s):

• On Monday, June 22nd, Louise Frederika Kooij sold 40,000 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $30.20, for a total value of $1,208,000.00.
• On Tuesday, May 26th, Louise Frederika Kooij sold 65,000 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $35.69, for a total value of $2,319,850.00.

NewAmsterdam Pharma Stock Performance

NASDAQ:NAMS opened at $27.98 on Wednesday. The stock has a 50-day simple moving average of $32.61 and a two-hundred day simple moving average of $32.78. NewAmsterdam Pharma Company N.V. has a 52-week low of $21.14 and a 52-week high of $42.21. The firm has a market capitalization of $3.27 billion, a PE ratio of -15.63 and a beta of 0.08.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its quarterly earnings data on Tuesday, March 31st. The company reported ($0.40) EPS for the quarter. NewAmsterdam Pharma had a negative return on equity of 26.49% and a negative net margin of 943.23%.The company had revenue of $3.04 million during the quarter. Equities analysts forecast that NewAmsterdam Pharma Company N.V. will post -1.78 earnings per share for the current fiscal year.

Institutional Trading of NewAmsterdam Pharma

Several institutional investors and hedge funds have recently added to or reduced their stakes in NAMS. Farther Finance Advisors LLC lifted its holdings in NewAmsterdam Pharma by 4,425.0% in the 4th quarter. Farther Finance Advisors LLC now owns 724 shares of the company’s stock worth $25,000 after purchasing an additional 708 shares in the last quarter. Wells Fargo & Company MN raised its position in shares of NewAmsterdam Pharma by 50.0% during the fourth quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock valued at $32,000 after buying an additional 300 shares during the last quarter. KBC Group NV purchased a new position in shares of NewAmsterdam Pharma in the first quarter worth $37,000. Navalign LLC purchased a new position in shares of NewAmsterdam Pharma in the fourth quarter worth $46,000. Finally, AdvisorNet Financial Inc purchased a new position in shares of NewAmsterdam Pharma in the first quarter worth $82,000. Institutional investors own 89.89% of the company’s stock.

Analyst Ratings Changes

A number of research firms have commented on NAMS. Jefferies Financial Group restated a “buy” rating and set a $45.00 target price on shares of NewAmsterdam Pharma in a research note on Monday, July 20th. Wall Street Zen upgraded shares of NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. BMO Capital Markets began coverage on shares of NewAmsterdam Pharma in a research note on Monday, July 20th. They issued an “outperform” rating and a $58.00 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research report on Friday, July 17th. Finally, Royal Bank Of Canada lifted their target price on shares of NewAmsterdam Pharma from $47.00 to $51.00 and gave the company an “outperform” rating in a research note on Tuesday, June 30th. Two investment analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $49.42.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.